Neuren Pharmaceuticals Limited (NEU) - Research

$1.115
Prices as at 15:46, 25 Apr 2019

NEU Current Share Price+

Current Price $1.115
Open $1.140
High $1.140
Low $1.110
Last Close $1.115
Volume 56291
Price Movement - ( No change )
  • +Security prices are delayed by at least 20 minutes and are indicative only.

NEU General Information

Neuren Pharmaceuticals Limited
NEU
http://www.neurenpharma.com
Pharmaceuticals
114
100

NEU Company Overview

Business Description

Neuren Pharmaceuticals Limited (NEU) is a biopharmaceutical company developing therapies for brain injury, neurodevelopmental and neurodegenerative disorders. NEU has two key drug products comprising NNZ-2566 and NNZ-2591. NEU has operations in New Zealand, Australia and the USA.

NEU Financial Summary

Year to Dec NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2020 F 0.00 -4.60 0.00% 0.00 0.00 0.00% 0.0%
2019 F 0.00 -12.70 0.00% 0.00 0.00 0.00% 0.0%
2018 A 3.07 3.10 -11.40% 74.30 0.00 0.00% 0.0%

NEU Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2018 A 2019 F 2020 F 2018 A 2019 F 2020 F 2018 A 2019 F 2020 F
Mayne Pharma Group (MYX) $1,084M -0.5645 0.2021 0.6145 23.8676 19.8551 12.2980 0.00% 0.00% 0.00%
Neuren Pharmaceuticals (NEU) $115M -0.1143 0.0000 0.0000 36.9355 0.0000 0.0000 0.00% 0.00% 0.00%
Starpharma (SPL) $476M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

NEU Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 1.20 0.00 4.64 0.00
Market 0.71 14.90 1.20 1.08
Sector 1.02 24.40 3.31 2.83

NEU Directors

Name Position Start Date
Dr Richard Spencer Treagus Executive Director, Executive Chairman 31 Jan 2013
Dr Trevor D Scott Non-Executive Director 5 Mar 2002
Ms Dianne Angus Non-Executive Director 1 Jul 2018
Dr Jenny Lee Harry Non-Executive Director 7 Jul 2018
Mr Patrick Davies Non-Executive Director 1 Jul 2018

NEU Management

Name Position
Jon Charles Pilcher Chief Financial Officer,Joint Company Secretary
James Shaw Vice President, Clinical Development
Nancy Jones Vice President, Clinical Development
Clive Blower Vice President, Product Development and Technical Affairs

NEU Substantial Shareholders

Holding Name
18,267,119 (17.94%) Langley Alexander Walker
6,565,123 (6.45%) Lanstead Capital LP

NEU Calendar of Events

Date Event
26 February 2020 Report (Prelim)
30 August 2019 Report (Interim)
07 May 2019 Report (Annual)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.